PATENT CLAIM ANALYSIS

Application Number: 15758187
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2019-01
Patent Classification: ["424", "185100"]

Abstract:
The present disclosure relates to CCL22 as a novel T cell target in cancer immunosuppression.

Claim (Index 21):
The vaccine composition according to  claim 1 , wherein the peptide fragment is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO:10, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 16 and functional homologues of any of the aforementioned, said functional homologue being a polypeptide of identical sequence wherein at most three amino acids have been substituted.

Metadata:
- Claim Count in Document: 16.0
- Percentile: 90.0
- Lexical Diversity: 1.0
- Patent Class: 424.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14352407', '15231075', '12988124', '10580016', '13031396']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8181780802950226
- 35 USC 102 Novelty (BERT): 0.5608454210587918
- Combined Prediction Score: 0.7924448143713996
- Mean Citation Score: 418.076916
- Max Citation Score: 477.45294
- Similarity Product: 341.71931603006243

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test